Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment. / Andreassen, B U; Paerregaard, A; Schmiegelow, K; Rechnitzer, C; Heilman, C; Hartmann, B; Holst, Jens Juul; Michaelsen, K F.
In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 40, No. 1, 01.2005, p. 48-53.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment
AU - Andreassen, B U
AU - Paerregaard, A
AU - Schmiegelow, K
AU - Rechnitzer, C
AU - Heilman, C
AU - Hartmann, B
AU - Holst, Jens Juul
AU - Michaelsen, K F
PY - 2005/1
Y1 - 2005/1
N2 - BACKGROUND: Intestinal dysfunction is frequent in cancer and during anti-cancer treatment. Glucagon-like peptide-2 (GLP-2) is secreted in a nutrition-dependent manner from the intestinal enteroendocrine L-cells. It accelerates crypt cell proliferation and nutrient absorption, inhibits enterocyte apoptosis and decreases mucosal permeability. Lack of GLP-2 may increase the risk of malabsorption and intestinal bacterial translocation. The aim of this study is to evaluate meal stimulated secretion of GLP-2 in children with cancer undergoing anti-cancer treatment.METHODS: Plasma-GLP-2 analysis after an overnight fast and 1 hour after intake of a mixed test meal. Data on gastrointestinal toxicity, blood neutrophile counts and food records were included in the analysis.RESULTS: Forty-four meal stimulation tests were performed in 25 children (median age, 6.0 years; range, 2.5-19) during anti-cancer treatment. Median GI toxicity score was 5 (range, 0-15), and mean energy intake was 62.4% of recommended values. P-GLP-2 values increased from mean (SD) 38 (18) to 63 (51) pmol/l (P < 0.0001). Twelve of the meal stimulation tests (28%) resulted in a p-GLP-2 increase >2 fold, which is assumed to be the lower limit of normal values. The increase was strongly dependent on the energy intake (r = 0.62, P < 0.0001), while toxicity score and neutrophile count had no significant influence (multiple regression).CONCLUSION: In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient. Insufficient GLP-2 secretion could influence the gastrointestinal problems seen in the children with a low enteral energy intake.
AB - BACKGROUND: Intestinal dysfunction is frequent in cancer and during anti-cancer treatment. Glucagon-like peptide-2 (GLP-2) is secreted in a nutrition-dependent manner from the intestinal enteroendocrine L-cells. It accelerates crypt cell proliferation and nutrient absorption, inhibits enterocyte apoptosis and decreases mucosal permeability. Lack of GLP-2 may increase the risk of malabsorption and intestinal bacterial translocation. The aim of this study is to evaluate meal stimulated secretion of GLP-2 in children with cancer undergoing anti-cancer treatment.METHODS: Plasma-GLP-2 analysis after an overnight fast and 1 hour after intake of a mixed test meal. Data on gastrointestinal toxicity, blood neutrophile counts and food records were included in the analysis.RESULTS: Forty-four meal stimulation tests were performed in 25 children (median age, 6.0 years; range, 2.5-19) during anti-cancer treatment. Median GI toxicity score was 5 (range, 0-15), and mean energy intake was 62.4% of recommended values. P-GLP-2 values increased from mean (SD) 38 (18) to 63 (51) pmol/l (P < 0.0001). Twelve of the meal stimulation tests (28%) resulted in a p-GLP-2 increase >2 fold, which is assumed to be the lower limit of normal values. The increase was strongly dependent on the energy intake (r = 0.62, P < 0.0001), while toxicity score and neutrophile count had no significant influence (multiple regression).CONCLUSION: In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient. Insufficient GLP-2 secretion could influence the gastrointestinal problems seen in the children with a low enteral energy intake.
KW - Adolescent
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Child
KW - Child, Preschool
KW - Diet Records
KW - Energy Intake
KW - Enteral Nutrition
KW - Female
KW - Glucagon-Like Peptide 2
KW - Glucagon-Like Peptides
KW - Humans
KW - Male
KW - Neoplasms
KW - Neutrophils
KW - Nutritional Requirements
KW - Nutritional Status
KW - Peptides
M3 - Journal article
C2 - 15625426
VL - 40
SP - 48
EP - 53
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
SN - 0277-2116
IS - 1
ER -
ID: 132054005